Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis

Modern Rheumatology

Volumn 24, Issue 1, 2014, Pages 106-111

  Takahashi, Takehiro ^a   Asano, Yoshihide ^a   Amiya, Eisuke ^a   Hatano, Masaru ^a   Tamaki, Zenshiro ^a   Takata, Munenori ^a   Ozeki, Atsuko ^a   Watanabe, Aya ^a   Kawarasaki, Shuichi ^a   Taniguchi, Takashi ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Watanabe, Masafumi ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a   Komuro, Issei ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Digital ulcers; Flow mediated dilation; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; ECHOGRAPHY; FEMALE; FINGER ULCER; FLOW MEDIATED DILATION; HUMAN; HYPEREMIA; IMMUNOSUPPRESSIVE TREATMENT; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; ULTRASOUND TRANSDUCER;

ADULT; AGED; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; SCLERODERMA, SYSTEMIC; VASODILATION;

EID: 84904988104     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.854064     Document Type: Article

References (32)

1. Asano Y. Future treatments in systemic sclerosis. J Dermatol. 2010;37:54-70.
2. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010;176: 1983-98.
3. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther. 2007;9(Suppl 2):S3.
4. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther. 2005;7:R1113-23.
5. Horn A, Distler JH. Vascular alterations upon activation of TGFbeta signaling in fibroblasts-implications for systemic sclerosis. Arthritis Res Ther. 2010;12:125.
6. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-5.
7. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-9.
8. Peng X, Haldar S, Deshpande S, Irani K, Kass DA. Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium. Hypertension. 2003;41:378-81.
9. Li M, Chiou KR, Bugayenko A, Irani K, Kass DA. Reduced wall compliance suppresses Akt-dependent apoptosis protection stimulated by pulse perfusion. Circ Res. 2005;97:587-95.
10. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flowmediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57:363-9.
11. Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol. 1998;82(1555-7):A8.
12. Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J. 1998;136:905-12.
13. Szucs G, Tímár O, Szekanecz Z, Dér H, Kerekes G, Szamosi S, et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology (Oxford). 2007;46:759-62.
14. Bartoli F, Blagojevic J, Bacci M, Fiori G, Tempestini A, Conforti ML, et al. Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci. 2007;1108: 283-90.
15. Rollando D, Bezante GP, Sulli A, Balbi M, Panico N, Pizzorni C, et al. Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol. 2010;37:1168-73.
16. Rossi P, Granel B, Marziale D, Le Mée F, Francés Y. Endothelial function and hemodynamics in systemic sclerosis. Clin Physiol Funct Imaging. 2010;30:453-9.
17. Cypiene A, Laucevicius A, Venalis A, Dadoniene J, Ryliskyte L, Petrulioniene Z, et al. The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol. 2008;27:1517-22.
18. Giannattasio C, Pozzi M, Gardinali M, Gradinali M, Montemerlo E, Citterio F, et al. Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens. 2007;25:793-7.
19. Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS, et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum. 2002;46:1324-32.
20. Roustit M, Simmons GH, Baguet JP, Carpentier P, Cracowski JL. Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol. 2008;35:1576-83.
21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-5.
22. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20:1892-6.
23. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56:1985-93.
24. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol. 1999;189:273-8.
25. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford). 2006;45:676-84.
26. Hasegawa M, Nagai Y, Tamura A, Ishikawa O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol. 2006;155:1159-64.
27. Stafford L, Englert H, Gover J, Bertouch J. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis. 1998; 57:476-9.
28. Youssef P, Englert H, Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis. 1993;52:464-6.
29. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis. 2012;71:1382-7.
30. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheumatology (Oxford). 2010;49:2375-80.
31. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum. 2003;48:2256-61.
32. Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowska D. Angiopoietins-1 and-2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford). 2011; 50:746-55.